Richard B Moss1, Patrick A Flume2, J Stuart Elborn3, Jon Cooke4, Steven M Rowe5, Susanna A McColley6, Ronald C Rubenstein7, Mark Higgins4. 1. Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: rmoss@stanford.edu. 2. Medical University of South Carolina, Charleston, SC, USA. 3. Queens University Belfast, Belfast, Northern Ireland, UK. 4. Vertex Pharmaceuticals (Europe) Ltd, Milton Park, UK. 5. University of Alabama at Birmingham, Birmingham, AL, USA. 6. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Abstract
BACKGROUND:Ivacaftor has been previously assessed in patients with cystic fibrosis with Gly551Asp-CFTR or other gating mutations. We assessed ivacaftor in patients with Arg117His-CFTR, a residual function mutation. METHODS: We did a 24-week, placebo-controlled, double-blind, randomised clinical trial, which enrolled 69 patients with cystic fibrosis aged 6 years and older with Arg117His-CFTR and percentage of predicted forced expiratory volume in 1 s (% predicted FEV1) of at least 40. We randomly assigned eligible patients (1:1) to receive placebo or ivacaftor 150 mg every 12 h for 24 weeks. Randomisation was stratified by age (6-11, 12-17, and ≥18 years) and % predicted FEV1 (<70, ≥70 to ≤90, and >90). The primary outcome was the absolute change from baseline in % predicted FEV1 through week 24. Secondary outcomes included safety and changes in sweat chloride concentrations and Cystic FibrosisQuestionnaire-Revised (CFQ-R) respiratory domain scores. An open-label extension enrolled 65 of the patients after washout; after 12 weeks, we did an interim analysis. FINDINGS: After 24 weeks, the treatment difference in mean absolute change in % predicted FEV1 between ivacaftor (n=34) and placebo (n=35) was 2·1 percentage points (95% CI -1·13 to 5·35; p=0·20). Ivacaftor treatment resulted in significant treatment differences in sweat chloride (-24·0 mmol/L, 95% CI -28·01 to -19·93; p<0·0001) and CFQ-R respiratory domain (8·4, 2·17 to 14·61; p=0·009). In prespecified subgroup analyses, % predicted FEV1 significantly improved with ivacaftor in patients aged 18 years or older (treatment difference vs placebo: 5·0 percentage points, 95% CI 1·15 to 8·78; p=0·01), but not in patients aged 6-11 years (-6·3 percentage points, -11·96 to -0·71; p=0·03). In the extension study, both placebo-to-ivacaftor and ivacaftor-to-ivacaftor groups showed % predicted FEV1 improvement (absolute change from post-washout baseline at week 12: placebo-to-ivacaftor, 5·0 percentage points [p=0·0005]; ivacaftor-to-ivacaftor, 6·0 percentage points [p=0·006]). We did not identify any new safety concerns. The studies are registered with ClinicalTrials.gov (the randomised, placebo-controlled study, number NCT01614457; the open-label extension study, number NCT01707290). INTERPRETATION: Although this study did not show a significant improvement in % predicted FEV1, ivacaftor did significantly improve sweat chloride and CFQ-R respiratory domain scores and lung function in adult patients with Arg117His-CFTR, indicating that ivacaftor might benefit patients with Arg117His-CFTR who have established disease. FUNDING: Vertex Pharmaceuticals Incorporated.
RCT Entities:
BACKGROUND:Ivacaftor has been previously assessed in patients with cystic fibrosis with Gly551Asp-CFTR or other gating mutations. We assessed ivacaftor in patients with Arg117His-CFTR, a residual function mutation. METHODS: We did a 24-week, placebo-controlled, double-blind, randomised clinical trial, which enrolled 69 patients with cystic fibrosis aged 6 years and older with Arg117His-CFTR and percentage of predicted forced expiratory volume in 1 s (% predicted FEV1) of at least 40. We randomly assigned eligible patients (1:1) to receive placebo or ivacaftor 150 mg every 12 h for 24 weeks. Randomisation was stratified by age (6-11, 12-17, and ≥18 years) and % predicted FEV1 (<70, ≥70 to ≤90, and >90). The primary outcome was the absolute change from baseline in % predicted FEV1 through week 24. Secondary outcomes included safety and changes in sweat chloride concentrations and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain scores. An open-label extension enrolled 65 of the patients after washout; after 12 weeks, we did an interim analysis. FINDINGS: After 24 weeks, the treatment difference in mean absolute change in % predicted FEV1 between ivacaftor (n=34) and placebo (n=35) was 2·1 percentage points (95% CI -1·13 to 5·35; p=0·20). Ivacaftor treatment resulted in significant treatment differences in sweat chloride (-24·0 mmol/L, 95% CI -28·01 to -19·93; p<0·0001) and CFQ-R respiratory domain (8·4, 2·17 to 14·61; p=0·009). In prespecified subgroup analyses, % predicted FEV1 significantly improved with ivacaftor in patients aged 18 years or older (treatment difference vs placebo: 5·0 percentage points, 95% CI 1·15 to 8·78; p=0·01), but not in patients aged 6-11 years (-6·3 percentage points, -11·96 to -0·71; p=0·03). In the extension study, both placebo-to-ivacaftor and ivacaftor-to-ivacaftor groups showed % predicted FEV1 improvement (absolute change from post-washout baseline at week 12: placebo-to-ivacaftor, 5·0 percentage points [p=0·0005]; ivacaftor-to-ivacaftor, 6·0 percentage points [p=0·006]). We did not identify any new safety concerns. The studies are registered with ClinicalTrials.gov (the randomised, placebo-controlled study, number NCT01614457; the open-label extension study, number NCT01707290). INTERPRETATION: Although this study did not show a significant improvement in % predicted FEV1, ivacaftor did significantly improve sweat chloride and CFQ-R respiratory domain scores and lung function in adult patients with Arg117His-CFTR, indicating that ivacaftor might benefit patients with Arg117His-CFTR who have established disease. FUNDING: Vertex Pharmaceuticals Incorporated.
Authors: N Morral; T Dörk; R Llevadot; V Dziadek; B Mercier; C Férec; B Costes; E Girodon; J Zielenski; L C Tsui; B Tümmler; X Estivill Journal: Hum Mutat Date: 1996 Impact factor: 4.878
Authors: Kris De Boeck; Anne Munck; Seth Walker; Albert Faro; Peter Hiatt; Geoffrey Gilmartin; Mark Higgins Journal: J Cyst Fibros Date: 2014-09-26 Impact factor: 5.482
Authors: N Rave-Harel; E Kerem; M Nissim-Rafinia; I Madjar; R Goshen; A Augarten; A Rahat; A Hurwitz; A Darvasi; B Kerem Journal: Am J Hum Genet Date: 1997-01 Impact factor: 11.025
Authors: S Kiesewetter; M Macek; C Davis; S M Curristin; C S Chu; C Graham; A E Shrimpton; S M Cashman; L C Tsui; J Mickle Journal: Nat Genet Date: 1993-11 Impact factor: 38.330
Authors: Bradley S Quon; Sabrina S Wilkie; Yannick Molgat-Seon; Michele R Schaeffer; Andrew H Ramsook; Pearce G Wilcox; Jordan A Guenette Journal: J Appl Physiol (1985) Date: 2015-10-01
Authors: Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2017-04-15 Impact factor: 21.405
Authors: Martina Gentzsch; Hong Y Ren; Scott A Houck; Nancy L Quinney; Deborah M Cholon; Pattarawut Sopha; Imron G Chaudhry; Jhuma Das; Nikolay V Dokholyan; Scott H Randell; Douglas M Cyr Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-07-08 Impact factor: 5.464
Authors: Meghan E McGarry; Beate Illek; Ngoc P Ly; Lorna Zlock; Sabrina Olshansky; Courtney Moreno; Walter E Finkbeiner; Dennis W Nielson Journal: Pediatr Pulmonol Date: 2017-01-09
Authors: S Vamsee Raju; Vivian Y Lin; Limbo Liu; Carmel M McNicholas; Suman Karki; Peter A Sloane; Liping Tang; Patricia L Jackson; Wei Wang; Landon Wilson; Kevin J Macon; Marina Mazur; John C Kappes; Lawrence J DeLucas; Stephen Barnes; Kevin Kirk; Guillermo J Tearney; Steven M Rowe Journal: Am J Respir Cell Mol Biol Date: 2017-01 Impact factor: 6.914
Authors: Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel Journal: J Cyst Fibros Date: 2016-10-27 Impact factor: 5.482
Authors: Venkateshwar Mutyam; Emily Falk Libby; Ning Peng; Denis Hadjiliadis; Michael Bonk; George M Solomon; Steven M Rowe Journal: J Cyst Fibros Date: 2016-10-01 Impact factor: 5.482